shutterstock_1124672624_jhvephoto
JHVEPhoto / Shutterstock.com
25 June 2019Americas

Teva infringed UCB patent, rules Fed Circuit

The US Court of Appeals for the Federal Circuit yesterday, June 24, upheld a lower court’s finding that UCB’s patent is infringed by a planned generic version of Neupro (rotigotine), a patch to treat Parkinson’s disease.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
14 October 2019   Belgium head-quartered pharmaceutical company UCB is to acquire Ra Pharmaceuticals for approximately $2.1 billion.
Americas
13 April 2023   Precedential decision upholds lower court’s earlier finding | Patent at heart of the dispute covers treatment patch for Parkinson’s.

More on this story

Big Pharma
14 October 2019   Belgium head-quartered pharmaceutical company UCB is to acquire Ra Pharmaceuticals for approximately $2.1 billion.
Americas
13 April 2023   Precedential decision upholds lower court’s earlier finding | Patent at heart of the dispute covers treatment patch for Parkinson’s.

More on this story

Big Pharma
14 October 2019   Belgium head-quartered pharmaceutical company UCB is to acquire Ra Pharmaceuticals for approximately $2.1 billion.
Americas
13 April 2023   Precedential decision upholds lower court’s earlier finding | Patent at heart of the dispute covers treatment patch for Parkinson’s.